Cargando...
KRAS biomarker testing disparities in colorectal cancer patients in New Mexico
INTRODUCTION: American Society of Clinical Oncology (ASCO) guidelines recommend that all patients with metastatic colorectal cancer (mCRC) receive KRAS testing to guide anti-EGFR monoclonal antibody treatment. The aim of this study was to assess for disparities in KRAS testing and mutational status....
Guardado en:
| Publicado en: | Heliyon |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Elsevier
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5701808/ https://ncbi.nlm.nih.gov/pubmed/29202108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.heliyon.2017.e00448 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|